Ausgabe 4/2020
Inhalt (12 Artikel)
An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure
Swan Lin, Naveed Shaik, Geoffrey Chan, Jorge E. Cortes, Ana Ruiz-Garcia
Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
Fan Wu, Gopal Krishna, Sekhar Surapaneni
Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors
Keith T. Schmidt, Alwin D. R. Huitema, Thomas P. C. Dorlo, Cody J. Peer, Lisa M. Cordes, Linda Sciuto, Susan Wroblewski, Yves Pommier, Ravi A. Madan, Anish Thomas, William D. Figg
Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer
Takahiro Tsushima, Hidefumi Kasai, Yusuke Tanigawara
Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer
Ludovic Fournel, Pascaline Boudou-Rouquette, Mathilde Prieto, Remi Hervochon, Claude Guinet, Jennifer Arrondeau, Jérôme Alexandre, Diane Damotte, Marie Wislez, Frédéric Batteux, Philippe Icard, François Goldwasser, Marco Alifano
Drug interactions with Bruton’s tyrosine kinase inhibitors: clinical implications and management
Karen M. Fancher, Jeremy J. Pappacena
Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms
Ryo Ariyasu, Noriko Yanagitani, Kenichi Tadokoro, Toshikazu Yamaguchi, Ken Uchibori, Satoru Kitazono, Naoya Fujita, Ryohei Katayama, Makoto Nishio
CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone
Stefania Crucitta, Marzia Del Re, Federico Paolieri, Francesco Bloise, Andrea Sbrana, Enrico Sammarco, Chiara Mercinelli, Federico Cucchiara, Lorenzo Fontanelli, Luca Galli, Romano Danesi
Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker
Anand Joshi, Jianxia Guo, Julianne L. Holleran, Brian Kiesel, Sarah Taylor, Susan Christner, Robert A. Parise, Brian M. Miller, S. Percy Ivy, Edward Chu, Raman Venkataramanan, Jan H. Beumer
Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer
Christina Teng, Stephanie E. Reuter, Prunella L. Blinman, Haryana M. Dhillon, Peter Galettis, Nicholas Proschogo, Andrew J. McLachlan, Janette L. Vardy
Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction
Tomoko Morita-Ogawa, Hiroki Sugita, Hironobu Minami, Takuhiro Yamaguchi, Kazuhiko Hanada
A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
Donghoon Shin, Yoon Jung Lee, Jihye Choi, Dahyoung Lee, Minjeong Park, Magdalena Petkova